{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T16:21:05Z","timestamp":1791994865526,"version":"4.4.0"},"reference-count":67,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2004,8,1]],"date-time":"2004-08-01T00:00:00Z","timestamp":1091318400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2004,8,1]],"date-time":"2004-08-01T00:00:00Z","timestamp":1091318400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal"],"published-print":{"date-parts":[[2004,8]]},"DOI":"10.1016\/j.ahj.2004.03.037","type":"journal-article","created":{"date-parts":[[2004,8,13]],"date-time":"2004-08-13T10:18:09Z","timestamp":1092392289000},"page":"211-221","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":66,"title":["The triglyceride\u2013high-density lipoprotein axis: An important target of therapy?"],"prefix":"10.1016","volume":"148","author":[{"given":"Philippe O.","family":"Szapary","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"Rader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ahj.2004.03.037_BIB1","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1001\/jama.285.19.2486","article-title":"Executive Summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)","volume":"285","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.ahj.2004.03.037_BIB2","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1161\/01.CIR.0000111245.75752.C6","article-title":"Definition of metabolic syndrome","volume":"109","author":"Grundy","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2004.03.037_BIB3","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0002-9149(00)01464-8","article-title":"High-density lipoprotein cholesterol as an independent risk factor in cardiovascular disease","volume":"86","author":"Boden","year":"2000","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ahj.2004.03.037_BIB4","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1001\/archinte.160.13.1937","article-title":"Do triglycerides provide meaningful information about heart disease risk?","volume":"160","author":"Avins","year":"2000","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.ahj.2004.03.037_BIB5","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1161\/01.CIR.97.11.1029","article-title":"Triglyceride concentration and ischemic heart disease","volume":"97","author":"Jeppesen","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2004.03.037_BIB6","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S0002-9149(00)00915-2","article-title":"Relation of serum triglyceride levels to survival after coronary artery bypass grafting","volume":"86","author":"Sprecher","year":"2000","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ahj.2004.03.037_BIB7","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1016\/S0002-9149(99)80761-9","article-title":"Distribution of lipids in 8,500 men with coronary artery disease","volume":"75","author":"Rubins","year":"1995","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ahj.2004.03.037_BIB8","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0002-9149(02)02634-6","article-title":"Lipoprotein disorders associated with type 2 diabetes mellitus and insulin resistance","volume":"90","author":"Haffner","year":"2002","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ahj.2004.03.037_BIB9","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1001\/jama.287.3.356","article-title":"Prevalence of the metabolic syndrome among US adults","volume":"287","author":"Ford","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.ahj.2004.03.037_BIB10","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0026-0495(96)90246-2","article-title":"Lipoproteins, apolipoproteins, and low-density lipoprotein size among diabetics in the Framingham offspring study","volume":"45","author":"Siegel","year":"1996","journal-title":"Metabolism"},{"key":"10.1016\/j.ahj.2004.03.037_BIB11","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/S0002-9149(96)00159-2","article-title":"Hypertriglyceridemia and elevated lipoprotein(a) are risk factors for major coronary events in middle-aged men","volume":"77","author":"Assmann","year":"1996","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ahj.2004.03.037_BIB12","doi-asserted-by":"crossref","first-page":"3046","DOI":"10.1161\/hc5001.100624","article-title":"Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S","volume":"104","author":"Ballantyne","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2004.03.037_BIB13","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0002-9149(00)01469-7","article-title":"Nonpharmacologic management of low levels of high-density lipoprotein cholesterol","volume":"86","author":"Ginsberg","year":"2000","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ahj.2004.03.037_BIB14","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1056\/NEJMoa022207","article-title":"A randomized trial of a low-carbohydrate diet for obesity","volume":"348","author":"Foster","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2004.03.037_BIB15","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1007\/s11886-003-0112-2","article-title":"Physical activity and its effects on lipids","volume":"5","author":"Szapary","year":"2003","journal-title":"Curr Cardiol Rep"},{"key":"10.1016\/j.ahj.2004.03.037_BIB16","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1007\/s11886-003-0112-2","article-title":"Physical Activity and Its Effects on Lipids","volume":"5","author":"Szapary","year":"2003","journal-title":"Curr Cardiol Rep"},{"key":"10.1016\/j.ahj.2004.03.037_BIB17","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1001\/jama.279.20.1615","article-title":"Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels","volume":"279","author":"Downs","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.ahj.2004.03.037_BIB18","doi-asserted-by":"crossref","unstructured":"MRC\/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7\u201322","DOI":"10.1016\/S0140-6736(02)09327-3"},{"key":"10.1016\/j.ahj.2004.03.037_BIB19","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S0140-6736(03)12948-0","article-title":"Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial\u2013Lipid Lowering Arm (ASCOT-LLA)","volume":"361","author":"Sever","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2004.03.037_BIB20","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/S0002-9149(03)00530-7","article-title":"Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial)","volume":"92","author":"Jones","year":"2003","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ahj.2004.03.037_BIB21","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1056\/NEJM198711123172001","article-title":"Helsinki Heart Study","volume":"317","author":"Frick","year":"1987","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2004.03.037_BIB22","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1056\/NEJM199908053410604","article-title":"Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol","volume":"341","author":"Rubins","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2004.03.037_BIB23","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1001\/jama.285.12.1585","article-title":"Relation of gemfibrozil treatment and lipid levels with major coronary events","volume":"285","author":"Robins","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.ahj.2004.03.037_BIB24","doi-asserted-by":"crossref","unstructured":"Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) Study. Circulation 2000;102:21\u20137","DOI":"10.1161\/01.CIR.102.1.21"},{"key":"10.1016\/j.ahj.2004.03.037_BIB25","doi-asserted-by":"crossref","unstructured":"Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet 2001;357:905\u201310","DOI":"10.1016\/S0140-6736(00)04209-4"},{"key":"10.1016\/j.ahj.2004.03.037_BIB26","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.2165\/00003495-200262130-00013","article-title":"Micronised fenofibrate","volume":"62","author":"Keating","year":"2002","journal-title":"Drugs"},{"key":"10.1016\/j.ahj.2004.03.037_BIB27","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1001\/archinte.160.8.1177","article-title":"Extended-release niacin vs gemfibrozil for the treatment of low levels of high-density lipoprotein cholesterol","volume":"160","author":"Guyton","year":"2000","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.ahj.2004.03.037_BIB28","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/S0735-1097(86)80293-5","article-title":"Fifteen year mortality in Coronary Drug Project patients","volume":"8","author":"Canner","year":"1986","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2004.03.037_BIB29","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1056\/NEJMoa011090","article-title":"Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease","volume":"345","author":"Brown","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2004.03.037_BIB30","doi-asserted-by":"crossref","first-page":"996","DOI":"10.7326\/0003-4819-139-12-200312160-00009","article-title":"Varying cost and free nicotinic acid content in over-the-counter niacin preparations for dyslipidemia","volume":"139","author":"Meyers","year":"2003","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ahj.2004.03.037_BIB31","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/S0026-0495(98)90284-0","article-title":"Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia","volume":"47","author":"Knopp","year":"1998","journal-title":"Metabolism"},{"key":"10.1016\/j.ahj.2004.03.037_BIB32","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1001\/jama.284.10.1263","article-title":"Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease","volume":"284","author":"Elam","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.ahj.2004.03.037_BIB33","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1001\/archinte.162.14.1568","article-title":"Efficacy, Safety, and tolerability of once-daily niaicin for the treatment of dyslipidemia associated with type 2 diabetes","volume":"162","author":"Grundy","year":"2002","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.ahj.2004.03.037_BIB34","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1093\/ajcn\/65.5.1645S","article-title":"n-3 fatty acids and serum lipoproteins","volume":"65","author":"Harris","year":"1997","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.ahj.2004.03.037_BIB35","first-page":"7","article-title":"Effects of atorvastatin and omega-3 fatty acids on LDL subfractions and postprandial hyperlipemia in patients with combined hyperlipemia","volume":"11","author":"Nordoy","year":"2001","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"10.1016\/j.ahj.2004.03.037_BIB36","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S0140-6736(99)07072-5","article-title":"Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction","volume":"354","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2004.03.037_BIB37","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1093\/ajcn\/77.2.300","article-title":"Randomized controlled trial of the effect of n-3 fatty acid supplementation on the metabolism of apolipoprotein B-100 and chylomicron remnants in men with visceral obesity","volume":"77","author":"Chan","year":"2003","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.ahj.2004.03.037_BIB38","first-page":"568","article-title":"ACC\/AHA\/NHLBI Clinical Advisory on the Use and Safety of Statins","volume":"40","author":"Pasternak","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2004.03.037_BIB39","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/S0002-9149(02)02970-3","article-title":"Combination therapy for dyslipidemia","volume":"90","author":"Davidson","year":"2002","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ahj.2004.03.037_BIB40","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/0002-9149(94)90005-1","article-title":"Comparative efficacy and safety of pravastatin nicotinic acid and the two combined in patients with hypercholesterolemia","volume":"73","author":"Davignon","year":"1994","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ahj.2004.03.037_BIB41","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/0002-9149(94)90088-4","article-title":"Fluvastatin with and without niacin for hypercholesterolemia","volume":"74","author":"Jacobson","year":"1994","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ahj.2004.03.037_BIB42","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/S0002-9149(99)80134-9","article-title":"Effects of pravastatin with niacin or magnesium on lipid levels and postprandial lipemia","volume":"76","author":"O'Keefe","year":"1995","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ahj.2004.03.037_BIB43","doi-asserted-by":"crossref","first-page":"529","DOI":"10.7326\/0003-4819-125-7-199610010-00001","article-title":"Effect of combination therapy with lipid-reducing drugs in patients with coronary heart disease and \u201cnormal\u201d cholesterol levels","volume":"125","author":"Pasternak","year":"1996","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ahj.2004.03.037_BIB44","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1177\/107424849600100204","article-title":"Efficacy and tolerability of low-dose simvastatin and niacin, alone and in combination, in patients with combined hyperlipidemia","volume":"1","author":"Stein","year":"1996","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"10.1016\/j.ahj.2004.03.037_BIB45","first-page":"231","article-title":"Complementary effects of pravastatin and nicotinic acid in the treatment of combined hyperlipidaemia in diabetic and non-diabetic patients","volume":"1","author":"Tsalamandris","year":"1994","journal-title":"J Cardiovasc Risk"},{"key":"10.1016\/j.ahj.2004.03.037_BIB46","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/S0002-9149(03)00007-9","article-title":"Comparison of Once-Daily, niacin Extended-Release\/lovastatin with standard doses of atorvastatin and simvastatin (the advicor versus other Cholesterol-Modulating agents trial evaluation","volume":"91","author":"Bays","year":"2003","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ahj.2004.03.037_BIB47","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S0002-9149(03)00111-5","article-title":"Effects of adding fenofibrate (200 mg\/day) to simvastatin (10 mg\/day) in patients with combined hyperlipidemia and metabolic syndrome","volume":"91","author":"Vega","year":"2003","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ahj.2004.03.037_BIB48","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1177\/174182670200900105","article-title":"Atorvastatin versus four statin-fibrate combinations in patients with familial combined hyperlipidaemia","volume":"9","author":"Athyros","year":"2002","journal-title":"J Cardiovasc Risk"},{"key":"10.1016\/j.ahj.2004.03.037_BIB49","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S0021-9150(00)00379-8","article-title":"Efficacy and safety of a combination of fluvastatin and bezafibrate in patients with mixed hyperlipidaemia (FACT study)","volume":"150","author":"Pauciullo","year":"2000","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.ahj.2004.03.037_BIB50","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/S0002-9149(97)00430-X","article-title":"Safety and efficacy of long-term statin-fibrate combinations in patients with refractory familial combined hyperlipidemia","volume":"80","author":"Athyros","year":"1997","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ahj.2004.03.037_BIB51","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S0002-9149(98)00040-X","article-title":"Long-term efficacy and safety of fenofibrate and a statin in the treatment of combined hyperlipidemia","volume":"81","author":"Ellen","year":"1998","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ahj.2004.03.037_BIB52","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0002-9149(99)00606-2","article-title":"Effect of combined fluvastatin-fenofibrate therapy compared with fenofibrate monotherapy in severe primary hypercholesterolemia","volume":"85","author":"Farnier","year":"2000","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ahj.2004.03.037_BIB53","doi-asserted-by":"crossref","unstructured":"Kayikcioglu M, Ozerkan F, Soydan I. Effectiveness and safety of alternate-day simvastatin and fenofibrate on mixed hyperlipidemia. Am J Cardiol 83:1135\u20137","DOI":"10.1016\/S0002-9149(99)00030-2"},{"key":"10.1016\/j.ahj.2004.03.037_BIB54","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/S0167-5273(99)00013-3","article-title":"Statin + fibrate combination therapy fluvastatin with bezafibrate or ciprofibrate in high risk patients with vascular disease","volume":"69","author":"Papadakis","year":"1999","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.ahj.2004.03.037_BIB55","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1001\/archinte.163.5.553","article-title":"Risk for myopathy with statin therapy in high-risk patients","volume":"163","author":"Ballantyne","year":"2003","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.ahj.2004.03.037_BIB56","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0378-4274(02)00010-3","article-title":"Myopathy and rhabdomyolysis with lipid-lowering drugs","volume":"128","author":"Hodel","year":"2002","journal-title":"Toxicol Lett"},{"key":"10.1016\/j.ahj.2004.03.037_BIB57","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1345\/aph.10315","article-title":"Statin-fibrate combination therapy","volume":"35","author":"Shek","year":"2001","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.ahj.2004.03.037_BIB58","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/S0002-9149(03)00885-3","article-title":"Effects of baseline level of triglycerides on changes in lipid levels from combined fluvastatin + fibrate (bezafibrate, fenofibrate, or gemfibrozil)","volume":"92","author":"Farnier","year":"2003","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ahj.2004.03.037_BIB59","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1046\/j.1365-2362.2002.01001.x","article-title":"Factorial study of the effects of atorvastatin and fish oil on dyslipidaemia in visceral obesity","volume":"32","author":"Chan","year":"2002","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.ahj.2004.03.037_BIB60","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.2337\/diacare.16.10.1387","article-title":"Metformin improves glucose, lipid metabolism, and reduces blood pressure in hypertensive, obese women","volume":"16","author":"Giugliano","year":"1993","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ahj.2004.03.037_BIB61","doi-asserted-by":"crossref","first-page":"920","DOI":"10.2337\/diacare.19.9.920","article-title":"The effect of metformin on the metabolic abnormalities associated with upper-body fat distribution","volume":"19","author":"Fontbonne","year":"1996","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ahj.2004.03.037_BIB62","doi-asserted-by":"crossref","first-page":"B64","DOI":"10.1016\/S0149-2918(03)80243-6","article-title":"Multicenter retrospective assess-ment of thiazolidinedione monotherapy and combination therapy in patients with type 2 diabetes","volume":"25","author":"Olansky","year":"2003","journal-title":"Clin Ther"},{"key":"10.1016\/j.ahj.2004.03.037_BIB63","doi-asserted-by":"crossref","first-page":"5503","DOI":"10.1210\/jc.2002-020963","article-title":"Effects of pioglitazone in non-diabetic patients with arterial hypertension","volume":"87","author":"Fullert","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ahj.2004.03.037_BIB64","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1177\/0091270003257230","article-title":"Ragaglitazar","volume":"43","author":"Skrumsager","year":"2003","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.ahj.2004.03.037_BIB65","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S0002-9149(03)00615-5","article-title":"Regulation of reverse cholesterol transport and clinical implications","volume":"92","author":"Rader","year":"2003","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ahj.2004.03.037_BIB66","doi-asserted-by":"crossref","unstructured":"Brousseau ME, Schaefer EJ, Wolfe ML, et al. Effects of a potent inhibitor of cholesteryl ester transfer protein on plasma lipoproteins in patients with low HDL cholesterol levels. N Engl J Med 2004;350:1505\u201315","DOI":"10.1056\/NEJMoa031766"},{"key":"10.1016\/j.ahj.2004.03.037_BIB67","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.1001\/jama.290.17.2322","article-title":"High-density lipoproteins as an emerging therapeutic target for atherosclerosis","volume":"290","author":"Rader","year":"2003","journal-title":"JAMA"}],"container-title":["American Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000287030400170X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000287030400170X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T05:06:34Z","timestamp":1757567194000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000287030400170X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,8]]},"references-count":67,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2004,8]]}},"alternative-id":["S000287030400170X"],"URL":"https:\/\/doi.org\/10.1016\/j.ahj.2004.03.037","relation":{},"ISSN":["0002-8703"],"issn-type":[{"value":"0002-8703","type":"print"}],"subject":[],"published":{"date-parts":[[2004,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The triglyceride\u2013high-density lipoprotein axis: An important target of therapy?","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ahj.2004.03.037","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"converted-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2004 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}